Description

Movespazm (simeticon, dicycloverine) Coated Tablets №20

Ingredients

Active ingredients: Simeticon, Dicycloverine

Dosage

Recommended dosage: Take 1 tablet by mouth as needed, up to 4 times daily.

Indications

Movespazm tablets are indicated for the relief of symptoms associated with irritable bowel syndrome (IBS) such as abdominal pain, bloating, and discomfort.

Contraindications

Do not use Movespazm tablets if you are allergic to any of the ingredients or if you have glaucoma.

Directions

Swallow the tablet whole with a glass of water. Do not crush or chew the tablet.

Scientific Evidence

Movespazm tablets contain simeticon and dicycloverine, which have been studied for their efficacy in managing symptoms of IBS. A study published in the “Journal of Gastroenterology” showed that dicycloverine significantly reduced abdominal pain and discomfort in patients with IBS compared to a placebo.

Additional Information

It is important to follow the recommended dosage and not exceed the maximum daily dose of Movespazm tablets. If symptoms persist or worsen, consult a healthcare professional for further evaluation.

Pharmacological Effects

Simeticon works by breaking down gas bubbles in the gastrointestinal tract, providing relief from bloating and gas. Dicycloverine is an antispasmodic that helps to relax the muscles in the intestines, reducing abdominal cramping and discomfort associated with IBS.

Clinical Trials and Comparative Effectiveness

In a comparative study published in the “American Journal of Gastroenterology,” dicycloverine was found to be as effective as other antispasmodic agents in reducing abdominal pain and bloating in patients with IBS. Movespazm tablets, with the combination of simeticon and dicycloverine, offer a comprehensive approach to managing IBS symptoms.

• Scientific evidence supports the efficacy of Movespazm tablets in relieving symptoms of IBS.
• The pharmacological actions of simeticon and dicycloverine provide targeted relief from gas, bloating, and abdominal discomfort.
• Clinical trials demonstrate the comparative effectiveness of dicycloverine in managing IBS symptoms.